From screening individual IL-17 inhibitor-related gastrointestinal inflammatory case reports, a total of 388 cases of primary suspect IL-17 inhibitor-associated inflammatory bowel disease and colitis were reported, of which 348 were SEC, 36 were IXE, and 4 were BRO. Here, IL17A is linked to inflammatory bowel disease.